Source: Palatin Technologies, Inc. and reported by http://www.prnewswire.com/
CRANBURY, N.J., Sept. 28, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that a poster entitled "Conditional cardiomyocyte-restricted Corin KO mice demonstrate enhanced cardiac hypertrophy and pro-fibrotic gene activation in response to TAC and PL-3994 – a novel selective GC-A receptor peptide agonist rescues the phenotype" was presented on Sunday, September 27, at the 2015 Heart Failure Society of American Annual Meeting in Washington, DC. PL-3994 is a synthetic natriuretic peptide receptor-A agonist developed by Palatin for treatment of heart failure and other indications.
The research work was done at Temple University School of Medicine in Philadelphia under the direction of Daniel L. Dries, M.D., and investigated the role of cardiomyocytes, corin and cardiac natriuretic peptide signaling in heart failure and the potential of treatment with PL-3994. The data presented demonstrated that corin and cardiac natriuretic peptides play an important role in regulating cardiac hypertrophy and fibrosis, and that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation.
Read more: http://www.prnewswire.com/news-releases/preclinical-data-on-pl-3994-for-heart-failure-and-resistant-hypertension-presented-at-2015-heart-failure-society-of-america-annual-meeting-300149516.html